Physician profile
Frederick C Atkinson
NPI 1811927957
$3,316.34
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,980 · 2020: $1,092 · 2021: $186 · 2022: $42.85 · 2024: $15.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $751.92 | 2019-2020 | |
| Glaxosmithkline, LLC. | $383.15 | 2019-2020 | |
| Novo Nordisk INC | $365.07 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $277.86 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.54 | 2019-2021 | |
| Amarin Pharma, INC. | $207.04 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $201.06 | 2019-2021 | |
| Lilly USA, LLC | $156.66 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $121.35 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.49 | 2019-2020 | |
| Amgen INC. | $79.58 | 2019-2024 | Krystexxa |
| Astellas Pharma US INC | $70.53 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $62.63 | 2019-2020 | |
| Genentech USA, INC. | $57.91 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $51.74 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $43.43 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.38 | 2019 | |
| Arbor Pharmaceuticals, INC. | $28.65 | 2019-2021 | |
| Dexcom, INC. | $26.00 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $13.95 | 2020 | |
| Currax Pharmaceuticals LLC | $13.85 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Atkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.